J&J | JNJ - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Abbott USD 68M 26M 2026-03
Amgen USD 657M 4M 2026-03
AstraZeneca USD 484M 181M 2025-12
Baxter International USD 58M 14M 2025-09
Bayer EUR 675M 87M 2025-12
Becton, Dickinson and Co. USD 149M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
Boston Scientific USD 90M 0 2026-03
Bristol-Myers Squibb USD 411M 21M 2026-03
CONMED USD 7.06M 310K 2026-03
Cooper Companies USD 20.9M 1.5M 2026-03
Dexcom USD 4.2M 500K 2025-12
Edwards Lifesciences USD 35.9M 2.7M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
Globus Medical USD 5.44B 5.44B 2026-03
Insulet USD 14.7M 5.5M 2026-03
Integra LifeSciences USD 22.46M 1.21M 2026-03
Intuitive Surgical USD 20.11B 58.39B 2026-03
J&J USD 43M 25M 2026-03
Medtronic USD 176M 5M 2026-03
Merck USD 479M 67M 2026-03
Merit Medical Systems USD 6.53M 162K 2026-03
Novartis USD 343M 39M 2026-03
Pfizer USD 671M 40M 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 178M 203M 2026-03
Stryker USD 46.29B 45.68B 2026-03
Tandem Diabetes Care USD 1.15B 1.15B 2026-03
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Zimmer Biomet Holdings USD 68.8M 3.1M 2026-03
Zoetis USD 62M 5M 2026-03